Cite
HARVARD Citation
Zhang, J. et al. (n.d.). 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). Immuno-oncology technology. p. . [Online].